drugset / Trial / NCT06849115

Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 Mutations

NCT06849115

Phase 4 Completed 4 enrolled ChaodongWang
NaSingle-groupOpen-labelTreatment

Summary

The study was designed as a single-center, open-label, single-arm pilot study to estimate the safety and efficacy L-carnitine in ALS patients with CHCHD10 mutations.

Timeline

Start
2024-07-18
Primary completion
2024-12-19
Completion
2025-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject L-carnitine Other / unclassified 1000 mg Intravenous